Skip to main content

Month: March 2022

Imperial Petroleum Announces Pricing of Upsized $60 Million Underwritten Public Offering

ATHENS, Greece, March 20, 2022 (GLOBE NEWSWIRE) — Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”) announced today the pricing of an upsized underwritten public offering of 37,500,000 units at a price of $1.60 per unit. Each unit consists of one common share (or prefunded warrant in lieu thereof) and one Class B warrant to purchase one common share, and will immediately separate upon issuance. The gross proceeds of the offering to the Company, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $60 million. The Company intends to use the net proceeds of the offering for capital expenditures, including acquisitions of additional vessels which we have not yet identified, and for other general corporate purposes. Each Class B warrant is immediately exercisable for one...

Continue reading

Barrick, Pakistan and Balochistan Agree in Principle to Restart Reko Diq Project

ISLAMABAD, Pakistan, March 20, 2022 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) and the governments of Pakistan and Balochistan have reached agreement on a framework that provides for the reconstitution of the Reko Diq project in the country’s Balochistan province. The project, which was suspended in 2011 due to a dispute over the legality of its licensing process, hosts one of the world’s largest undeveloped open pit copper-gold porphyry deposits. The reconstituted project will be held 50% by Barrick and 50% by Pakistan stakeholders, comprising a 10% free-carried, non-contributing share held by the government of Balochistan, an additional 15% held by a special purpose company owned by the government of Balochistan and 25% owned by other federal state-owned enterprises. A separate agreement provides for Barrick’s...

Continue reading

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress

BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that study overview and baseline data from ACT-AD, a fully enrolled Phase 2 clinical trial of Athira’s lead development candidate, fosgonimeton (ATH-1017) in study participants with mild-to-moderate Alzheimer’s disease (AD), were presented in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Diseases (AD/PD™ 2022) taking place in Barcelona, Spain, and virtually from March 15-20, 2022. Of the 77 study participants enrolled in the randomized, double-blind, placebo-controlled trial, the mean age is 71.4 years, with 50.6% female...

Continue reading

Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities

VANCOUVER, British Columbia, March 19, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) announces that following its recently announced developments it is actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies. “Acquisition or investment by a major pharmaceutical company could be mutually beneficial. As more research comes to light regarding the use of psychedelics to treat depression, addiction, as well as other mental health and cognitive disorders, the market size for psychedelic drugs will increase, and large pharmaceutical companies could look to consolidate the industry to ensure they have a strong drug pipeline in the future,” stated Joel Shacker, Core One CEO. About...

Continue reading

Kandy Joins Project “CAMARA – The Telco Global API Alliance”

Project to address industry API interoperability in collaboration with GSMA and the Linux Foundation ATLANTA, March 18, 2022 (GLOBE NEWSWIRE) — American Virtual Cloud Technologies, Inc.’s (Nasdaq: AVCT) announced that its Kandy Communications business unit (Kandy), has joined the new, open source project: “CAMARA – The Telco Global API Alliance.” The global partnership will address challenges in porting and reproducing API services across heterogenous operator and cloud architectures. Kandy provides global carrier/operator grade white-label cloud communications services including CPaaS, UCaaS, CCaaS, Microsoft Teams Direct Routing as a Service, SIP Trunking services, and a rich portfolio of real-time communications APIs and supporting functions. CAMARA is the latest project introduced by The Linux Foundation, the nonprofit...

Continue reading

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (NASDAQ: ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern Time on May 26, 2022. Additional information regarding the Company’s 2022 Annual Meeting of Stockholders will be disclosed in the Company’s Proxy Statement to be filed with the Securities and Exchange Commission. About Adagio Therapeutics Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians...

Continue reading

Ambev’s 2021 Annual Report on Form 20-F Available on Our Website

SÃO PAULO, Brazil, March 18, 2022 (GLOBE NEWSWIRE) — Ambev S.A. [B3: ABEV3; NYSE: ABEV] announces that the Company’s annual report on Form 20-F for the year ended December 31, 2021 was filed with the U.S. Securities and Exchange Commission – SEC (www.sec.gov) on March 18, 2022 and is available on the Company’s website (ri.ambev.com.br) and also on the Company’s page on SEC’s database (www.sec.gov/edgar/). ADR holders may receive a hard copy of the Company’s complete audited financial statements contained in the Form 20-F free of charge, upon request. To access the full document, please access the following link: click here CONTACT: Ambev S.A. Investor Relations Department Contact e-mail: ri@ambev.com.br

Continue reading

O2Micro Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

GEORGE TOWN, Grand Cayman, March 18, 2022 (GLOBE NEWSWIRE) — O2Micro® International Limited (NASDAQ Global Select Market: OIIM) (“O2Micro” or the “Company”), a global leader in the design, development and marketing of high-performance integrated circuits and solutions, today announced that its board of directors (the “Board”) has received a preliminary non-binding proposal letter (the “Proposal Letter”), dated March 14, 2022, from FNOF Precious Honour Limited (together with its affiliated investment entities, “FNOF”), to acquire all of the outstanding shares of the Company (including American Depositary Share (“ADS”) for a purchase price of US$5.50 per ADS, or US$0.11 per ordinary share, in cash (the “Proposed Transaction”). A copy of the Proposal Letter is attached hereto as Exhibit A. The Board has formed a special committee...

Continue reading

The Flowr Corporation Announces Business Update and Leadership Transition

TORONTO, March 18, 2022 (GLOBE NEWSWIRE) — The Flowr Corporation (“Flowr” or the “Company”) (TSXV: FLWR, OTC: FLWPF) is pleased to provide a business update and announces the departure of Director and Chief Executive Officer (“CEO”) Darryl Brooker and appointment of Tom Flow as Interim CEO. Business Update In the last six months, Flowr has increased its product offerings significantly with the launch and success of Strawnana, Sour Sis, BC Dog Walkers, and the recently introduced strains of BC Clementine Crush, BC Lemon Ice, BC Spiced Grape and BC Mango Melon OG. Q2 will see the introduction of seven new SKU’s across the provinces of Ontario, Quebec, British Columbia, Alberta and Saskatchewan. The genetic and innovation pipeline continues to expand and new product launches are planned for Q3 and Q4. From January 2022 to February...

Continue reading

Fitch Revises Iceland’s Outlook to Stable; Affirms at ‘A’

Fitch Ratings has affirmed Iceland’s Long-Term Foreign-Currency Issuer Default Rating (IDR) at ‘A’ and revised the Rating Outlook to Stable from Negative. The revision of the Outlook to Stable reflects the resilience shown by the Icelandic economy to the pandemic shock and Fitch‘s expectation of a sustained growth recovery which should facilitate fiscal deficit and debt reduction over time. The Icelandic economy has proved more resilient to the pandemic shock relative to Fitch‘s initial expectations. The recovery is underpinned by a rebound in tourism flows, solid performance of the aluminium sector supported by high aluminium prices, improvement of the labour market and sizeable fiscal policy support. Private consumption and investment will remain the main growth drivers, supported by further declines in unemployment and the government’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.